Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.42)
# 2,442
Out of 5,245 analysts
53
Total ratings
36.59%
Success rate
4.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Initiates: Overweight | n/a | $14.53 | - | 1 | Mar 24, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $29.37 | +151.96% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $4.24 | - | 1 | Oct 16, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $16.62 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $48.13 | - | 1 | Jul 17, 2025 | |
| RNA Atrium Therapeutics | Reiterates: Overweight | $96 | $13.07 | +634.51% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.83 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $11.62 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $22.02 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $21.68 | -39.99% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.39 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $50.36 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $97.16 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.14 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.24 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $28.83 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $193.76 | +50.70% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $434.52 | -14.85% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.76 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.47 | - | 1 | May 30, 2017 |
Generate Biomedicines
Mar 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $14.53
Upside: -
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $29.37
Upside: +151.96%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $4.24
Upside: -
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.62
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $48.13
Upside: -
Atrium Therapeutics
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $13.07
Upside: +634.51%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.83
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.62
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.02
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $21.68
Upside: -39.99%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.39
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $50.36
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $97.16
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.14
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.24
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $28.83
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $193.76
Upside: +50.70%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $434.52
Upside: -14.85%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.76
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.47
Upside: -